Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
745.7 USD | +1.96% | -0.14% | +27.92% |
Apr. 23 | Global markets live: Bayer, PepsiCo, Halliburton, Spotify, Apple... | |
Apr. 23 | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With an expected P/E ratio at 60.22 and 40.82 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+27.92% | 672B | C+ | ||
+27.68% | 570B | B | ||
-4.59% | 360B | C+ | ||
+16.38% | 321B | B- | ||
+9.39% | 300B | C+ | ||
+6.30% | 217B | B+ | ||
+4.80% | 199B | B- | ||
-6.05% | 204B | A+ | ||
-8.58% | 149B | C+ | ||
-4.99% | 147B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LLY Stock
- Ratings Eli Lilly and Company